$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx

$nanx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000183988223007887 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$9.457M	$8.261M	$37.32M
YoY Change	15.95%	12.17%	26.61%
Cost Of Revenue	$7.308M	$7.298M	$28.96M
YoY Change	22.04%	17.77%	39.32%
Gross Profit	$2.149M	$963.0K	$8.360M
YoY Change	-0.88%	-17.55%	-3.8%
Gross Profit Margin	22.72%	11.66%	22.4%
Selling, General & Admin	$2.150M	$2.088M	$7.581M
YoY Change	53.9%	131.49%	94.58%
% of Gross Profit	100.05%	216.82%	90.68%
Research & Development	$1.003M	$727.0K	$3.037M
YoY Change	50.6%	28.67%	35.88%
% of Gross Profit	46.67%	75.49%	36.33%
Depreciation & Amortization	$174.0K	$154.0K	$567.0K
YoY Change	27.94%	22.22%	24.89%
% of Gross Profit	8.1%	15.99%	6.78%
Operating Expenses	$3.153M	$2.815M	$10.62M
YoY Change	52.84%	91.89%	73.19%
Operating Profit	-$1.004M	-$1.852M	-$2.258M
YoY Change	-1056.19%	519.4%	-188.24%
Interest Expense	$155.0K	-$150.0K	$382.0K
YoY Change	-460.47%	158.62%	-133.1%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	-$1.159M	-$2.002M	-$2.640M
YoY Change	-1969.35%	460.78%	-212.01%
Income Tax		-$17.00K	-$17.00K
% Of Pretax Income
Net Earnings	-$1.159M	-$1.985M	-$2.623M
YoY Change	-1969.35%	403.81%	-213.06%
Net Earnings / Revenue	-12.26%	-24.03%	-7.03%
Basic Earnings Per Share	-$0.02		-$0.05
Diluted Earnings Per Share	-$0.02	-$0.04	-$0.05
COMMON SHARES
Basic Shares Outstanding	49.51M shares	49.23M shares	49.12M shares
Diluted Shares Outstanding	49.43M shares		49.12M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.094M	$2.186M	$2.186M
YoY Change	21.96%	232.72%	232.72%
Cash & Equivalents	$1.094M	$2.186M	$2.186M
Short-Term Investments
Other Short-Term Assets	$933.0K	$866.0K	$866.0K
YoY Change	-7.16%	-4.84%	-4.84%
Inventory	$8.118M	$8.839M	$8.839M
Prepaid Expenses
Receivables	$4.380M	$4.734M	$4.734M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.53M	$16.63M	$16.63M
YoY Change	-7.69%	43.33%	43.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.235M	$7.949M	$16.93M
YoY Change	-50.73%	68.7%	0.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.000K	$6.000K	$6.000K
YoY Change	-42.86%	-25.0%	-25.0%
Total Long-Term Assets	$16.95M	$16.93M	$16.93M
YoY Change	1.38%	0.82%	0.82%
TOTAL ASSETS
Total Short-Term Assets	$14.53M	$16.63M	$16.63M
Total Long-Term Assets	$16.95M	$16.93M	$16.93M
Total Assets	$31.48M	$33.56M	$33.56M
YoY Change	-3.02%	18.19%	18.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.032M	$6.363M	$6.363M
YoY Change	21.78%	78.44%	78.44%
Accrued Expenses	$1.132M	$1.023M	$1.023M
YoY Change	-38.84%	8.14%	-65.07%
Deferred Revenue
YoY Change
Short-Term Debt	$6.892M	$7.282M	$7.282M
YoY Change	85.82%	439.01%	439.01%
Long-Term Debt Due	$1.000M	$0.00	$0.00
YoY Change	1328.57%		-100.0%
Total Short-Term Liabilities	$16.86M	$16.84M	$16.84M
YoY Change	47.52%	129.36%	92.75%
LONG-TERM LIABILITIES
Long-Term Debt		$1.000M	$1.000M
YoY Change			-0.6%
Other Long-Term Liabilities	$10.02M	$10.07M	$10.07M
YoY Change	-18.38%	-9.97%	-9.97%
Total Long-Term Liabilities	$10.02M	$11.07M	$11.07M
YoY Change	-24.55%	-18.51%	-9.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.86M	$16.84M	$16.84M
Total Long-Term Liabilities	$10.02M	$11.07M	$11.07M
Total Liabilities	$26.88M	$27.91M	$27.91M
YoY Change	8.79%	33.35%	33.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.4M	-$100.1M
YoY Change		2.69%
Common Stock	$495.0K	$493.0K
YoY Change		0.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.597M	$5.649M	$5.649M
YoY Change
Total Liabilities & Shareholders Equity	$31.48M	$33.56M	$33.56M
YoY Change	-3.02%	18.19%	18.19%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.159M	-$1.985M	-$2.623M
YoY Change	-1969.35%	403.81%	-213.06%
Depreciation, Depletion And Amortization	$174.0K	$154.0K	$567.0K
YoY Change	27.94%	22.22%	24.89%
Cash From Operating Activities	-$782.0K	$747.0K	-$1.650M
YoY Change	-55.94%	-63.6%	-171.09%
INVESTING ACTIVITIES
Capital Expenditures	$21.00K	$1.025M	$2.823M
YoY Change	-105.56%	-338.93%	-250.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$21.00K	-$1.025M	-$2.823M
YoY Change	-94.44%	138.93%	50.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$289.0K	1.954M	$6.002M
YoY Change	-112.08%	-183.29%	-903.48%
NET CHANGE
Cash From Operating Activities	-$782.0K	747.0K	-$1.650M
Cash From Investing Activities	-$21.00K	-1.025M	-$2.823M
Cash From Financing Activities	-$289.0K	1.954M	$6.002M
Net Change In Cash	-$1.092M	1.676M	$1.529M
YoY Change	-555.0%	-331.81%	-609.67%
FREE CASH FLOW
Cash From Operating Activities	-$782.0K	$747.0K	-$1.650M
Capital Expenditures	$21.00K	$1.025M	$2.823M
Free Cash Flow	-$803.0K	-$278.0K	-$4.473M
YoY Change	-42.52%	-111.21%	-206.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000883107
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022	nanx	Proceeds From Related Party Term Loan ProceedsFromRelatedPartyTermLoan		usd
CY2022	nanx	Conversion Of Convertible Loan Related Party ConversionOfConvertibleLoanRelatedParty		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations		usd
CY2021	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations		usd
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2021	us-gaap	Sublease Income SubleaseIncome		usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome		usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment		usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness		usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome		usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-22333
CY2022	dei	Entity Registrant Name EntityRegistrantName	NANOPHASE TECHNOLOGIES CORPORATION
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3687863
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1319 Marquette Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Romeoville
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60446
CY2022	dei	City Area Code CityAreaCode	630
CY2022	dei	Local Phone Number LocalPhoneNumber	771-6708
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	47927272	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49505124	shares
CY2022	dei	Auditor Name AuditorName	RSM US LLP
CY2022	dei	Auditor Firm AuditorFirmId	49
CY2022	dei	Auditor Location AuditorLocation	Chicago, Illinois
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2186000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	657000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	139000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	60000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4734000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3937000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	8839000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	6095000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	866000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	910000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	16625000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11599000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7949000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4712000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8978000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12075000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8000	usd
CY2022Q4	us-gaap	Assets Assets	33558000	usd
CY2021Q4	us-gaap	Assets Assets	28394000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	7282000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1351000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6363000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3566000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2167000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	783000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1023000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	946000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16835000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7340000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9823000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11700000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1000000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	21000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	661000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	230000	usd
CY2021Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	222000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11074000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13589000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49320680	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49320680	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48893573	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48893573	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	493000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	489000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105226000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104423000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100070000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97447000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5649000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7465000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33558000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28394000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37317000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29475000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28957000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20785000	usd
CY2022	us-gaap	Gross Profit GrossProfit	8360000	usd
CY2021	us-gaap	Gross Profit GrossProfit	8690000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3037000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2235000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7581000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3896000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2258000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2559000	usd
CY2022	us-gaap	Interest Expense InterestExpense	382000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1154000	usd
CY2021	us-gaap	Other Income OtherIncome	952000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2640000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2357000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2623000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2320000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49117000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45021173	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49117000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47039173	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2732000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	234000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2019000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2320000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7465000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7465000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	182000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	625000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2623000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2623000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5649000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5649000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2623000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2320000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	567000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	454000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	952000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	903000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	625000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	160000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	797000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1005000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2744000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1755000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-44000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	304000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1826000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1026000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	744000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1033000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	77000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	481000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	631000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-40000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1650000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2321000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2823000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1874000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2823000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1874000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	111000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	177000	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1000000	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	500000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	29594000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25554000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35525000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	24750000	usd
CY2021	nanx	Proceeds From Related Party Term Loan ProceedsFromRelatedPartyTermLoan	500000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	182000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	234000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6002000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-747000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1529000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-300000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	657000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	957000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2186000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	657000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	333000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	218000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	971000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	414000	usd
CY2021	nanx	Conversion Of Convertible Loan Related Party ConversionOfConvertibleLoanRelatedParty	2000000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	19000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zEzIv0y6FbMl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)</b></span></td> <td id="xdx_826_zg8RpTqyAXUf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, as testing for various viruses, most notably COVID-19, has become a critical use of our technology.<span style="text-decoration: line-through"> </span> Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We target markets<span style="text-decoration: line-through">,</span> primarily related to skin health products and ingredients<span style="text-decoration: line-through">,</span> as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded a net loss and negative cash flow from operations in 2022. Management believes that <span style="background-color: white">current liquidity and available borrowing capacity are sufficient to fund operations and there is not substantial doubt regarding the Company’s ability to continue as a going concern.</span></span></p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zS1ToS6P9LIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zIshiWXrJP49">Use of Estimates and Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</span></p>
CY2022Q4	us-gaap	Deferred Income DeferredIncome	2188000	usd
CY2021Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	222000	usd
CY2020Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	214000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	8000	usd
CY2021	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	8000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	230000	usd
CY2021Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	222000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3937000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1444000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4734000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2188000	usd
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2932000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	411000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3937000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1444000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	667000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	260000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2051000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2018000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2623000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2320000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49117000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45021173	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2018000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49117000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47039173	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zijZHWk12Saa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zh9YKG5AqJP8">Reclassification from prior period</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reclassified a portion of the current ROU liability to non-current as of December 31, 2021, to be consistent with the classifications at December 31, 2022. This reclassification resulted in a decrease of $<span id="xdx_90A_eus-gaap--LiabilitiesCurrent_iNI_pn3n3_di_c20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zIJxCrSnYmM2" title="Total current liabilities">1,394</span> to “Current portion of operating lease obligations” and “Total current liabilities” and an increase in “Long-term portion of operating lease liabilities” and “Total long-term liabilities” of $<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z4ARXgDnHU2k" title="Long-term operating lease obligations">1,394</span>. The current and long-term portion of operating lease obligations were previously presented as $<span id="xdx_904_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zZSjwacsNvz2" title="Current operating lease obligations">1,983</span> and $<span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z9Rcgx3m0jK6" title="Long-term operating lease obligations">10,306</span>, respectively in the December 31, 2021 financial statements. The current and long-term portion of operating lease obligations have been retrospectively presented as $<span id="xdx_905_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20211231_zE60YE7YxpWl" title="Current operating lease obligations">589</span> and $<span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_zTHjgUcKg5I1" title="Long-term operating lease obligations">11,700</span>, respectively, as of December 31, 2021.</span></p>
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11700000	usd
CY2022	nanx	Related Party Interest Expense RelatedPartyInterestExpense	356000	usd
CY2021	nanx	Related Party Interest Expense RelatedPartyInterestExpense	1129000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	49000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	13000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6797000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4413000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2041000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1682000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	8839000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	6095000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29115000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25322000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21166000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20610000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7949000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4712000	usd
CY2022	us-gaap	Depreciation Depreciation	557000	usd
CY2021	us-gaap	Depreciation Depreciation	444000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8978000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9823000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Tenant Improvements TenantImprovements	1957000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	97000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12075000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11700000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	33000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	52000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	18000	usd
CY2022	nanx	Lease Costs Finance LeaseCostsFinance	37000	usd
CY2021	nanx	Lease Costs Finance LeaseCostsFinance	70000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2068000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	554000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	536000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	134000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	138000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	49000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	689000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2053000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	737000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2090000	usd
CY2021	us-gaap	Lease Cost LeaseCost	807000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1433000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	741000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	12000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	10505000	usd
CY2022	nanx	Early Termination Of Operating Lease EarlyTerminationOfOperatingLease	73000	usd
CY2022	nanx	Reduction In Right Of Use Asset Due To Remeasurement ReductionInRightOfUseAssetDueToRemeasurement	1793000	usd
CY2022	nanx	Reduction In Lease Liability Due To Remeasurement ReductionInLeaseLiabilityDueToRemeasurement	1898000	usd
CY2021Q4	us-gaap	Lessee Finance Lease Remaining Lease Term LesseeFinanceLeaseRemainingLeaseTerm	P0Y8M12D
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P9Y7M6D
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P9Y6M
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.093	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	97000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2029000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1473000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1471000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1510000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7162000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13742000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3919000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9823000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	288000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	471000	usd
CY2022Q4	nanx	Customer Net Volume Rebate Payable CustomerNetVolumeRebatePayable	403000	usd
CY2021Q4	nanx	Customer Net Volume Rebate Payable CustomerNetVolumeRebatePayable	320000	usd
CY2022Q4	nanx	Tenant Security Deposit TenantSecurityDeposit	61000	usd
CY2021Q4	nanx	Tenant Security Deposit TenantSecurityDeposit	122000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	271000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1023000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	946000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-551000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	495000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	271000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-273000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-63000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-124000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	177000	usd
CY2022	nanx	Income Tax Reconciliation Tax Credits Expiration IncomeTaxReconciliationTaxCreditsExpiration	1149000	usd
CY2021	nanx	Income Tax Reconciliation Tax Credits Expiration IncomeTaxReconciliationTaxCreditsExpiration	899000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	69000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	75000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	92000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-15000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-347000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1294000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	253000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	253000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13416000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	117000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	98000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	202000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	177000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	148000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	31000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	59000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	63000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	480000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	394000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	308000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	238000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	161000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15181000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15277000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14928000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15277000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-300000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1300000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	5500000	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	1000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	56000000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.035	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.014	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.16	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.15	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.59
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3193216	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	768400	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.61
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	414455	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.44
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	103500	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3443661	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1230000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2193254	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.86
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1126000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1119100	shares
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	153000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	107000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	2973000	usd
CY2021Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	2462000	usd
CY2022Q4	nanx	Equipment Sale Net Book Value Equipment EquipmentSaleNetBookValueEquipment	1.15	pure
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37317000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29475000	usd

Files In Submission

Name	View Source	Status
0001839882-23-007887-index-headers.html	Edgar Link	pending
0001839882-23-007887-index.html	Edgar Link	pending
0001839882-23-007887.txt	Edgar Link	pending
0001839882-23-007887-xbrl.zip	Edgar Link	pending
ex10-22.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nanx-10k_123122.htm	Edgar Link	pending
nanx-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nanx-20221231_cal.xml	Edgar Link	unprocessable
nanx-20221231_def.xml	Edgar Link	unprocessable
nanx-20221231_lab.xml	Edgar Link	unprocessable
nanx-20221231_pre.xml	Edgar Link	unprocessable
nanx-10k_123122_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx

2023 Q1 Form 10-K Financial Statement

#000183988223007887 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NANX NANOPHASE TECHNOLOGIES Corp Stock $nanx

2023 Q1 Form 10-K Financial Statement

#000183988223007887 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx